GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its fourth quarter and year-end earnings results after market
close on Tuesday, March 11, 2014. Management will hold a conference call
to review the Company's financial performance starting at 4:30 p.m. EDT
on the same day. The conference call will be concurrently webcast. The
link to the webcast will be available on the GenMark Diagnostics, Inc.
website at www.genmarkdx.com
undr the investor relations section and will be archived for future
reference. To listen to the conference call, please dial (877) 312-5847
(US/Canada) or (253) 237-1154 (International) and use the conference ID
number "6963720" approximately five minutes prior to the start time.
GenMark Diagnostics is a leading provider of automated, multiplex
molecular diagnostic testing systems that detect and measure DNA and RNA
targets to diagnose disease and optimize patient treatment. Utilizing
GenMark's proprietary eSensor® detection technology, GenMark's eSensor®
XT-8 system is designed to support a broad range of molecular diagnostic
tests with a compact, easy-to-use workstation and self-contained,
disposable test cartridges. GenMark currently markets four tests that
are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test,
Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin
Sensitivity Test. A number of other tests, including HCV Genotyping,
2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
[ Back To NFVZone's Homepage ]